RESTRICTING EXTRACELLULAR CA2+ ON GEFITINIB RESISTANT NON-SMALL CELL LUNG CANCER CELLS REVERSES ALTERED EPIDERMAL GROWTH FACTOR MEDIATED CA2+ RESPONSE, WHICH CONSEQUENTLY ENHANCES GEFITINIB SENSITIVITY
نویسندگان
چکیده
TOPIC: Lung Cancer TYPE: Original Investigations PURPOSE: Non-small cell lung cancer (NSCLC), one of the leading causes cancer-related death, has a low 5-year survival rate owing to inevitable acquired resistance toward antitumor drugs, platinum-based chemotherapy, and targeted therapy. Epidermal growth factor (EGF)-EGF receptor (EGFR) signaling activates downstream events phospholipase C/inositol trisphosphate (IP3)/Ca2+ release from IP3-sensitive Ca2+ stores modulate proliferation, motility, invasion. However, role EGFR-mediated in drug is not fully understood. METHODS: We analyzed intracellular calcium ([Ca2+]i) signals PC-9 cells PC-9/GR (Gefitinib Resistant) under following conditions. observed hEGF (200ng/ml)-mediated [Ca2+]i oscillations response. Calcium influx, endoplasmic reticulum (ER) contents, (200 ng/ml)-mediated oscillations, effects inhibitors were studied absence extracellular ([Ca2+]e). compared gefitinib-induced cytotoxicity viability according presence or [Ca2+]e. RESULTS: NSCLC gefitinib resistant cells, we found that acute EGF treatment elicited but cells. presented more sustained basal level, lower higher spontaneous ([Ca2+]e) influx than Notably, restricting [Ca2+]e both types induced identical dependent on C EGFR activation. Consequently, upregulated gefitinib-mediated poly (ADP-ribose) polymerase cleavage, an increase Bax/Bcl-2 ratio, cytotoxicity, apoptosis. In addition, nuclear activated T (NFAT1) induction response was inhibited by whereas EGF-mediated NFAT1 regardless treatment. Restricting significantly reduced induction. CONCLUSIONS: These findings indicate plays pivotal developing suggest may be potential strategy for modulating drug-sensitivity. CLINICAL IMPLICATIONS: mechanism TKI DISCLOSURES: no disclosure file Misung Kim; Sohui Minsuk No relevant relationships Seihoon Yang, source=Web Response
منابع مشابه
Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib, are effective for non-small cell lung cancer (NSCLC) patients with EGFR mutations. However, these patients eventually develop resistance to EGFR-TKI. The goal of the present study was to investigate the involvement of autophagy in gefitinib resistance. We developed gefitinib-resistant cells (PC-9/gef) ...
متن کاملGefitinib in Non Small Cell Lung Cancer
Gefitinib is an oral, reversible, tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) that plays a key role in the biology of non small cell lung cancer (NSCLC). Phase I studies indicated that the recommended dose of gefitinib was 250 mg/day. Rash, diarrhea, and nausea were the most common adverse events. The positive results obtained in early phase 2 clinical trials with gefit...
متن کاملEpidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.
PURPOSE Epidermal growth factor receptor (EGFR) mRNA expression and EGFR gene dosage by quantitative PCR in tumor samples obtained from patients with gefitinib-treated non-small cell lung cancer were analyzed in order to determine the association with treatment outcome, clinical, and biological features [EGFR copy number by fluorescent in situ hybridization (FISH), EGFR tyrosine kinase mutation...
متن کاملEverolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines.
The epidermal growth factor receptor (EGFR) is a validated target for therapy in non-small cell lung cancer (NSCLC). Most patients, however, either do not benefit or develop resistance to specific inhibitors of the EGFR tyrosine kinase activity, such as gefitinib or erlotinib. The mammalian target of rapamycin (mTOR) is a key intracellular kinase integrating proliferation and survival pathways ...
متن کاملImpaired SHP2-Mediated Extracellular Signal-Regulated Kinase Activation Contributes to Gefitinib Sensitivity of Lung Cancer Cells with Epidermal Factor Receptor-
Most non-small cell lung cancers (NSCLC) display elevated expression of epidermal growth factor receptor (EGFR), but response to EGFR kinase inhibitors is predominantly limited to NSCLC harboring EGFR-activating mutations. These mutations are associated with increased activity of survival pathways including PI3K/AKT and STAT3/5. We report that EGFR-activating mutations also surprisingly lead to...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Chest
سال: 2021
ISSN: ['0012-3692', '1931-3543']
DOI: https://doi.org/10.1016/j.chest.2021.07.1489